You have free access to this content

Cancer

Cover image for Cancer

1 February 2009

Volume 115, Issue 3

Pages 465–697

  1. News

    1. Top of page
    2. News
    3. Editorial
    4. Review Article
    5. Original Articles
    1. You have free access to this content
      CancerScope (pages 465–467)

      Carrie Printz

      Version of Record online: 20 JAN 2009 | DOI: 10.1002/cncr.24058

  2. Editorial

    1. Top of page
    2. News
    3. Editorial
    4. Review Article
    5. Original Articles
    1. You have free access to this content
      Stereotactic radiotherapy for pancreatic cancer? (pages 468–472)

      Christopher H. Crane and Christopher G. Willett

      Version of Record online: 31 DEC 2008 | DOI: 10.1002/cncr.24069

      Although the authors of 1 report in this issue have proposed the use of stereotactic body radiotherapy (SBRT) for patients with pancreatic cancer, other authors have associated SBRT with poor outcomes, unacceptable toxicity, and questionable palliative effect. The results of this study do not support the use of SBRT for pancreatic cancer outside of a clinical trial setting.

  3. Review Article

    1. Top of page
    2. News
    3. Editorial
    4. Review Article
    5. Original Articles
    1. You have free access to this content
      Bendamustine : A new look at an old drug (pages 473–479)

      Matt Kalaycio

      Version of Record online: 31 DEC 2008 | DOI: 10.1002/cncr.24057

      Bendamustine is a unique alkylating agent with significant activity against indolent B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. This review summarizes the available literature regarding clinical use and outcomes.

  4. Original Articles

    1. Top of page
    2. News
    3. Editorial
    4. Review Article
    5. Original Articles
    1. Disease Site

      Breast Disease
      You have free access to this content
      Cancer surveillance behaviors and psychosocial factors among long-term survivors of breast cancer : Cancer and Leukemia Group B 79804 (pages 480–488)

      Mira L. Katz, Kathleen A. Donohue, Catherine M. Alfano, Jeannette M. Day, James E. Herndon II and Electra D. Paskett

      Version of Record online: 9 JAN 2009 | DOI: 10.1002/cncr.24063

      Many long-term breast cancer survivors were not within recommended cancer surveillance guidelines. There were no significant differences in psychological symptoms between survivors who complied and who did not comply with breast cancer surveillance; however, survivors who complied with recommended pelvic examination guidelines, compared with survivors who did not comply, were younger, married, had health insurance, and had lower levels of psychological symptoms.

    2. You have free access to this content
      Cost-effectiveness analysis of lapatinib in HER-2–positive advanced breast cancer (pages 489–498)

      Quang A. Le and Joel W. Hay

      Version of Record online: 31 DEC 2008 | DOI: 10.1002/cncr.24033

      • original image
      • original image
      • original image
      • original image
      • original image

      The addition of lapatinib to capecitabine in the treatment of human epidermal growth factor receptor-2–positive advanced breast cancer (ABC) significantly increases median time to progression. The current cost-utility analysis estimated that from a lifetime, US societal perspective, treatment with lapatinib in ABC resulted in a cost of $166,113 per quality-adjusted life year gained; that is not clearly cost-effective and most likely higher than many commonly accepted willingness-to-pay thresholds in oncology treatments.

    3. You have free access to this content
      Benign breast lesions at risk of developing cancer—A challenging problem in breast cancer screening programs : Five years' experience of the Breast Cancer Screening Program in Verona (1999-2004) (pages 499–507)

      Erminia Manfrin, Renata Mariotto, Andrea Remo, Daniela Reghellin, Francesca Falsirollo, Daniela Dalfior, Paola Bricolo, Elena Piazzola and Franco Bonetti

      Version of Record online: 30 DEC 2008 | DOI: 10.1002/cncr.24038

      • original image

      Cytology and core-needle biopsies are not always sufficient to exclude malignancy in benign breast lesions (BBL) that are at risk of developing cancer, and open biopsy often is mandatory. The results from this study indicated that it is inappropriate to include BBL at risk of developing cancer in the overall benign open biopsy rate, and the authors propose separating pure BBL from lesions that are at higher risk for developing cancer.

    4. Gastrointestinal Disease
      You have free access to this content
      Esophageal tumor length is independently associated with long-term survival (pages 508–516)

      Sai Yendamuri, Stephen G. Swisher, Arlene M. Correa, Wayne Hofstetter, Jaffer A. Ajani, Ashleigh Francis, Dipen Maru, Reza J. Mehran, David C. Rice, Jack A. Roth, Garrett L. Walsh and Ara A. Vaporciyan

      Version of Record online: 31 DEC 2008 | DOI: 10.1002/cncr.24062

      • original image
      • original image
      • original image

      Esophageal tumor length is independently associated with long-term survival. The incorporation of esophageal tumor length significantly improves the ability of the esophageal cancer staging system to predict long-term survival and to identify high-risk patients for postoperative therapy.

    5. Genitourinary Disease
      You have free access to this content
      Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients (pages 517–523)

      Giuseppe Di Lorenzo, Vincenzo Montesarchio, Riccardo Autorino, Teresa Bellelli, Nicola Longo, Ciro Imbimbo, Emilio Morelli, Gianluca Giannarini, Vincenzo Mirone and Sabino De Placido

      Version of Record online: 31 DEC 2008 | DOI: 10.1002/cncr.24055

      A phase 1/2 study was conducted of paclitaxel in combination with oral cyclophosphamide for patients with advanced urothelial bladder cancer who had been previously treated with the combination of gemcitabine/cisplatin as first-line metastatic treatment. Paclitaxel-cyclophosphamide combination was well tolerated and associated with promising efficacy. Further trials are needed to confirm our preliminary results.

    6. Gynecologic Oncology
      You have free access to this content
      Long-term incidence of cervical cancer in women with human immunodeficiency virus (pages 524–530)

      L. Stewart Massad, Eric C. Seaberg, D. Heather Watts, Howard Minkoff, Alexandra M. Levine, Donna Henry, Christine Colie, Teresa M. Darragh and Nancy A. Hessol

      Version of Record online: 6 JAN 2009 | DOI: 10.1002/cncr.24067

      When they were included in a prospective study that incorporated cancer prevention measures, human immunodeficiency virus (HIV)-positive women were found to have cervical cancer incidence rates similar to those of HIV-negative women.

    7. You have free access to this content
      Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin (pages 531–539)

      Celeste Leigh Pearce, Karine Chung, Malcolm C. Pike and Anna H. Wu

      Version of Record online: 6 JAN 2009 | DOI: 10.1002/cncr.23956

      • original image
      • original image
      • original image

      Menopausal estrogen therapy use increases risk of ovarian cancer in a duration-dependent manner, and it appears that progestins can, at least to some extent, block this action. Whether the effect of estrogens would be completely blocked if progestins were given every day is unclear.

    8. Head and Neck Disease
      You have free access to this content
      Prognostic index for patients with parotid carcinoma : International external validation in a Belgian-German database (pages 540–550)

      Vincent Vander Poorten, Augustinus Hart, Tom Vauterin, Gert Jeunen, Joseph Schoenaers, Marc Hamoir, Alphonsus Balm, Eberhard Stennert, Orlando Guntinas-Lichius and Pierre Delaere

      Version of Record online: 9 JAN 2009 | DOI: 10.1002/cncr.24015

      • original image
      • original image

      International external validation of a previously developed prognostic index for parotid carcinoma supported its generalizability, reproducibility, transportability, and, thus, its prospective generalized application.

    9. Hematologic Malignancies
      You have free access to this content
      Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase (pages 551–560)

      Hagop M. Kantarjian, Richard A. Larson, Francois Guilhot, Stephen G. O'Brien, Manisha Mone, Marc Rudoltz, Tillmann Krahnke, Jorge Cortes, Brian J. Druker and for the International Randomized Study of Interferon and STI571 (IRIS) Investigators

      Version of Record online: 31 DEC 2008 | DOI: 10.1002/cncr.24066

      • original image
      • original image

      Dose escalation of imatinib has been proposed for patients with chronic myeloid leukemia in chronic phase who fail to demonstrate an optimal response or progress on standard-dose imatinib. This retrospective analysis of patients on the International Randomized Study of Interferon and STI571 trial who underwent dose escalation demonstrated a clinical benefit for patients who experienced suboptimal response of cytogenetic relapse on standard-dose imatinib.

      Corrected by:

      Erratum: Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

      Vol. 116, Issue 15, 3750, Version of Record online: 21 APR 2010

    10. You have free access to this content
      The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (pages 561–570)

      Seok Lee, Yoo-Jin Kim, Nak-Gyun Chung, Jihyang Lim, Dong-Gun Lee, Hee-Je Kim, Chang-Ki Min, Jong-Wook Lee, Woo-Sung Min and Chun-Choo Kim

      Version of Record online: 31 DEC 2008 | DOI: 10.1002/cncr.24026

      • original image
      • original image

      A reduction in BCR-ABL transcript levels of at least 3 log after the first 4-week imatinib therapy was identified as the most powerful predictor of transplantation outcome in terms of lower relapse (12.1% vs 45.1%, P = .011) and better disease-free survival (82.1% vs 41.7%, P = .009) rates in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. If this is verified, it would be interesting to study whether the inclusion of newer tyrosine kinase inhibitors into chemotherapy schedules according to the extent of minimal residual disease reduction at this stage modifies the overall transplantation outcome.

    11. Hepatobiliary Disease
      You have free access to this content
      High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma (pages 571–580)

      Masahiro Kobayashi, Kenji Ikeda, Yusuke Kawamura, Hiromi Yatsuji, Tetsuya Hosaka, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase and Hiromitsu Kumada

      Version of Record online: 31 DEC 2008 | DOI: 10.1002/cncr.24031

      • original image
      • original image
      • original image

      High levels of des-gamma-carboxy prothrombin in patients with hepatocellular tumors reflect the biologic aggressiveness and progression of the tumor. Such patients should be treated with surgical resection rather than with radiofrequency ablation.

    12. Lung Disease
      You have free access to this content
      Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival (pages 581–586)

      Katherine R. Birchard, Jenny K. Hoang, James E. Herndon Jr and Edward F. Patz Jr

      Version of Record online: 31 DEC 2008 | DOI: 10.1002/cncr.24060

      • original image
      • original image

      Sequential tumor measurements are currently used to guide therapy in patients with advanced stage nonsmall cell lung cancer and that new criteria are needed to determine response.

    13. You have free access to this content
      Outcomes of stereotactic radiotherapy for a new clinical stage I lung cancer arising postpneumonectomy (pages 587–594)

      Cornelis J. A. Haasbeek, Frank J. Lagerwaard, Katrien de Jaeger, Ben J. Slotman and Suresh Senan

      Version of Record online: 6 JAN 2009 | DOI: 10.1002/cncr.24068

      • original image
      • original image
      • original image

      Resection of second lung tumors after previous pneumonectomy has been associated with a high risk of complications. The results from this study demonstrated that stereotactic radiation therapy is a safe and effective treatment for these patients.

    14. You have free access to this content
      Genetic susceptibility of lung cancer associated with common variants in the 3′ untranslated regions of the adenosine triphosphate-binding cassette B1 (ABCB1) and ABCC1 candidate transporter genes for carcinogen export (pages 595–607)

      Haijian Wang, Guangfu Jin, Haifeng Wang, Gaifen Liu, Ji Qian, Li Jin, Qingyi Wei, Hongbing Shen, Wei Huang and Daru Lu

      Version of Record online: 23 DEC 2008 | DOI: 10.1002/cncr.24042

      Adenosine triphosphate-binding cassette B1 (ABCB1) and ABCC1 are candidate transporter genes for carcinogen export. The results from this case-control study suggested that their common variants, at least those in the 3′ untranslated regions, are associated with a risk of lung cancer.

    15. Discipline

      Clinical Trials
      You have free access to this content
      Diversity of participants in clinical trials in an academic medical center : The role of the ‘Good Study Patient?’ (pages 608–615)

      Galen Joseph and Daniel Dohan

      Version of Record online: 6 JAN 2009 | DOI: 10.1002/cncr.24028

      Clinical investigators play a major role in recruiting patients to therapeutic clinical trials. The results from this in-depth study of recruitment practices suggested that clinicians make subjective judgments about which patients are more able to complete complex study protocols and, thus, which patients constitute ‘good study patients’ to target for trials recruitment.

    16. Diagnostic Imaging
      You have free access to this content
      Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma : Are response evaluation criteria in solid tumors reliable? (pages 616–623)

      Alejandro Forner, Carmen Ayuso, María Varela, Jordi Rimola, Amelia J. Hessheimer, Carlos Rodriguez de Lope, María Reig, Luís Bianchi, Josep M. Llovet and Jordi Bruix

      Version of Record online: 30 DEC 2008 | DOI: 10.1002/cncr.24050

      The objective of this study was to compare the concordance/agreement of tumor response evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) versus European Association for the Study of the Liver guidelines in a cohort of patients who received locoregional therapy, including percutaneous ablation (by ethanol injection or radiofrequency) and transarterial chemoembolization, for hepatocellular carcinoma. The results indicated that RECIST has no value in this assessment of tumor response after locoregional therapies in patients with hepatocellular carcinoma and this evaluation should incorporate the reduction in viable tumor burden as recognized by nonenhanced areas by dynamic imaging studies.

    17. You have free access to this content
      Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation (pages 624–630)

      Heta Javeri, Lianchun Xiao, Eric Rohren, Ritsuko Komaki, Wayne Hofstetter, Jeffrey H. Lee, Dipen Maru, Manoop S. Bhutani, Stephen G. Swisher, Xuemei Wang and Jaffer A. Ajani

      Version of Record online: 6 JAN 2009 | DOI: 10.1002/cncr.24056

      • original image

      Lower initial standard unit value (iSUV) of 18F-fluoro-2-deoxy-D-glucose positron emission tomography is associated with poor survival and lower probability of response to chemoradiation in patients with esophageal adenocarcinoma. iSUV may complement other methods of prognosticating patient outcome.

    18. Pathology
      You have free access to this content
      The atypical Spitz tumor of uncertain biologic potential : A series of 67 patients from a single institution (pages 631–641)

      Mathew W. Ludgate, Douglas R. Fullen, Julia Lee, Lori Lowe, Carol Bradford, James Geiger, Jennifer Schwartz and Timothy M. Johnson

      Version of Record online: 5 JAN 2009 | DOI: 10.1002/cncr.24047

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Atypical Spitz tumors are rare spitzoid melanocytic proliferations with an uncertain malignant potential. This study reveals a high incidence of microscopic lymph node deposits in sentinel lymph node biopsies performed for atypical Spitz tumors, but despite this finding, patients have a favorable prognosis.

    19. Pediatric Oncology
      You have free access to this content
      Promoting physical activity in childhood cancer survivors : Results from the Childhood Cancer Survivor Study (pages 642–654)

      Cheryl L. Cox, Michele Montgomery, Kevin C. Oeffinger, Wendy Leisenring, Lonnie Zeltzer, John A. Whitton, Ann C. Mertens, Melissa M. Hudson and Leslie L. Robison

      Version of Record online: 31 DEC 2008 | DOI: 10.1002/cncr.24043

      • original image
      • original image
      • original image

      The authors investigated the modifiable factors that influenced the participation of childhood cancer survivors in physical activity. The results indicated that gender-tailored intervention strategies in which providers specifically target motivation, fear, and affect may support physical activity in childhood cancer survivors.

    20. You have free access to this content
      Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors (pages 655–664)

      Lisa M. McGregor, Sheri L. Spunt, Victor M. Santana, Clinton F. Stewart, Deborah A. Ward, Amy Watkins, Fred H. Laningham, Percy Ivy, Wayne L. Furman and Maryam Fouladi

      Version of Record online: 31 DEC 2008 | DOI: 10.1002/cncr.24054

      • original image
      • original image

      This phase 1, dose-finding study in children with recurrent solid tumors found that maximum tolerated doses were oxaliplatin at a dose of 130 mg/m2 on Day 1 in combination with etoposide at a dose of 100 mg/m2/d on Days 1 through 3 of a 21-day course. The dose-limiting toxicity was neutropenia, and there was evidence of antitumor activity.

    21. Radiation Oncology
      You have free access to this content
      Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas (pages 665–672)

      Daniel T. Chang, Devin Schellenberg, John Shen, Jeff Kim, Karyn A. Goodman, George A. Fisher, James M. Ford, Terry Desser, Andrew Quon and Albert C. Koong

      Version of Record online: 31 DEC 2008 | DOI: 10.1002/cncr.24059

      • original image
      • original image
      • original image

      The authors report their experience using stereotactic body radiotherapy with 25 grays in 1 fraction for patients with unresectable pancreatic adenocarcinoma. The rates of 1-year freedom from local progression and 1-year overall survival were 84% and 21%, respectively, with 11% and 25% grade ≥2 late toxicity rates at 6 months and 12 months, respectively, indicating the efficacy of this treatment but with associated risks.

    22. You have free access to this content
      Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival : Results from a Canadian randomized trial (pages 673–679)

      Juanita M. Crook, Shawn Malone, Gad Perry, Libni Eapen, Julie Owen, Susan Robertson, Charles Ludgate, Sharon Fung and Gina Lockwood

      Version of Record online: 30 DEC 2008 | DOI: 10.1002/cncr.24020

      • original image

      Two-year postradiation prostate biopsies were strongly predictive of subsequent disease-free survival. Biopsies with severe treatment effect were considered negative.

    23. You have free access to this content
      The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma : Analysis of the spread patterns in lymph nodes by magnetic resonance imaging (pages 680–688)

      Linglong Tang, Yanping Mao, Lizhi Liu, Shaobo Liang, Yong Chen, Ying Sun, Xinbiao Liao, Aihua Lin, Mengzhong Liu, Li Li and Jun Ma

      Version of Record online: 31 DEC 2008 | DOI: 10.1002/cncr.24049

      • original image
      • original image
      • original image

      This magnetic resonance imaging-based study demonstrated that lymph node (LN) metastases spread in an orderly fashion from higher level LNs to lower level LNs. The results did not support prophylactic irradiation of Level IV and supraclavicular fossa LNs in patients who were negative for LN metastases, and these concepts need to be tested clinically before that may be recommended generally.

    24. Symptom Control and Palliative Care
      You have free access to this content
      Race, treatment preferences, and hospice enrollment: Eligibility criteria may exclude patients with the greatest needs for care (pages 689–697)

      Jessica Fishman, Peter O'Dwyer, Hien L. Lu, Hope Henderson, David A. Asch and David J. Casarett

      Version of Record online: 23 DEC 2008 | DOI: 10.1002/cncr.24046

      • original image
      • original image
      • original image

      This study was conducted to determine whether African-American patients with cancer are more likely than white patients are to have preferences for cancer treatment that exclude them from hospice and whether they are less likely to want specific hospice services. The results suggested that African-American patients with cancer are more likely than white patients to want aggressive cancer treatment, that they had greater perceived needs for specific hospice services compared with white patients, and that the greater perceived need for hospice services among African Americans was attributable largely to differences in self-reported finances.

SEARCH

SEARCH BY CITATION